miR-181a在卵巢癌组织中的表达及临床意义

Expression of miR-181a in Ovarian Cancer and Its Clinical Significance

目的:分析miR-181a在卵巢癌组织中的表达并探究其与临床特征之间的关系。方法:选取我院妇科2011-2013年治疗的30例卵巢癌恶性肿瘤患者的卵巢组织为卵巢癌组,选取同期术中诊断卵囊巢浆液性或黏液性囊腺瘤行卵巢切除的卵巢组织为对照组。提取两组患者卵巢组织中的总RNA后通过microRNA茎环引物进行逆转录,实时荧光定量PCR(q-PCR)技术检测正常组织与卵巢癌组织中miR-181a的表达,并分析不同临床特征中miR-181a的表达差异。结果:miR-181a在卵巢癌中表达显著升高,相对正常组表达量(2-ΔΔCt值)为20.620±1.242。上皮性卵巢癌组织中,高分化卵巢癌miR-181a的表达明显低于中、低分化组织;病理分期Ⅰ、Ⅱ期的卵巢癌患者miR-181a表达明显低于Ⅲ、Ⅳ;存在淋巴转移的患者miR-181a表达明显高于无淋巴转移的患者;术前CA-125<1 000μmol/L的患者miR-181a表达明显低于CA-125>1 000μmol/L的患者;腹水量<1 000ml的患者miR-181a的表达明显低于腹水量>1 000ml的患者,以上差异均有统计学意义(P<0.05)。结论:miR-181a在卵巢癌组织中表达差异明显,并与患者FIGO分期、组织分级、淋巴转移、术前CA-125等临床特征相关,提示它可能参与调节卵巢癌的发生、发展并可能成为卵巢癌治疗的一个潜在靶点。

Objective： To analyze the miR-181a expression in ovarian cancer and to explore its relationship to the clinical features. Methods： Thirty cases of ovarian cancer and another group of benign ovarian tumor tissues including oocysts nest serous or mucinous cystadenoma were involved in this study. Pathological and clinical features were reviewed in ovarian cancer group. Q-PCR was adopted to detect miR-181a expression. Results： Expression of miR-181a was significantly in- creased in ovarian cancer. The expression level of miR-181a was lower in well differentiated, low- er pathological staged, and non lymph node metastasis ovarian cancer. And the expression was also lower in the cases with CA-125〈1 000 tamol/L before operation and ascites volume 〈1 000 ml （P〈0.05）. Conclusion： miR-181a is differentially expressed in ovarian cancer with different clinical and pathological characteristics. It may be involved in the regulation of ovarian cancer development and may become a potential target for the treatment of ovarian cancer.